1.29
-0.07 (-5.15%)
| Previous Close | 1.36 |
| Open | 1.35 |
| Volume | 6,877,240 |
| Avg. Volume (3M) | 9,297,380 |
| Market Cap | 823,041,920 |
| Price / Sales | 5.13 |
| Price / Book | 3.12 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -119.54% |
| Operating Margin (TTM) | -42.18% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 12,927.30% |
| Total Debt/Equity (MRQ) | 45.40% |
| Current Ratio (MRQ) | 7.86 |
| Operating Cash Flow (TTM) | -204.34 M |
| Levered Free Cash Flow (TTM) | -142.38 M |
| Return on Assets (TTM) | -16.07% |
| Return on Equity (TTM) | -45.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Geron Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -2.25 |
|
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.09% |
| % Held by Institutions | 81.26% |
| 52 Weeks Range | ||
| Median | 1.00 (-22.48%) | |
| Total | 1 Sell | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 10 Jul 2025 | 1.00 (-22.48%) | Sell | 1.38 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Geron to Participate in the 2025 Wells Fargo Healthcare Conference |
| 18 Aug 2025 | Announcement | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 Aug 2025 | Announcement | Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Aug 2025 | Announcement | Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights |
| 28 Jul 2025 | Announcement | Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025 |
| 18 Jul 2025 | Announcement | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 18 Jun 2025 | Announcement | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |